Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$12.80 USD
+1.25 (10.82%)
Updated May 14, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
STOK 12.80 +1.25(10.82%)
Will STOK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STOK
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Other News for STOK
Buy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial Stability
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...
Promising Efficacy of STK-001 in Refractory Epilepsy Bolsters Buy Rating
Buy Rating for Stoke Therapeutics with Adjusted Price Target Amid Regulatory and Developmental Progress